Reproducibility of p53 immunohistochemistry in bladder tumors

被引:0
作者
McShane, LM
Aamodt, R
Cordon-Cardo, C
Cote, R
Faraggi, D
Fradet, Y
Grossman, HB
Peng, A
Taube, SE
Waldman, FM
机构
[1] NCI, Biometr Res Branch, Bethesda, MD 20892 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Univ So Calif, Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[4] Univ Haifa, IL-31905 Haifa, Israel
[5] Univ Laval, Quebec City, PQ G1R 2J6, Canada
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Emmes Corp, Potomac, MD 20854 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Institute Bladder Tumor Marker Network conducted a study to evaluate the reproducibility of immunohistochemistry for measuring p53 expression in bladder tumors, Fifty paraffin blocks (10 from each of the five network institutions) were chosen at random from among high-grade invasive primary bladder tumors. Two sections from each block were sent to each laboratory for staining and scoring, and then all sections were randomly redistributed among the laboratories for a second scoring. Intra- and interlaboratory reproducibility was assessed with regard to both staining and scoring, For overall assessments of p53 positivity, the results demonstrated that intralaboratory reproducibility was quite good. Concordance across the five participating laboratories was high for specimens exhibiting no or minimal nuclear immunostaining of tumor cells or high percentages of tumor cells with nuclear immunoreactivities. However, there was a reduced level of concordance on specimens with percentages of stained tumor cells in an intermediate range. The discordancies mere due mainly to staining differences in one of the five laboratories and scoring differences in another laboratory. These results indicate that some caution must be used in comparing results across studies from different groups. Standardization of staining protocols and selection of a uniform threshold for binary interpretation of results may improve assay reproducibility between laboratories.
引用
收藏
页码:1854 / 1864
页数:11
相关论文
共 50 条
[21]   p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant [J].
Hodgson, Anjelica ;
Xu, Bin ;
Downes, Michelle R. .
HISTOPATHOLOGY, 2017, 71 (02) :296-304
[22]   Abnormal/wild type p53 immunohistochemistry shows high specificity and positive predictive value for p53 mutation status: time to reassess p53 thresholds in bladder cancer [J].
Downes, M. ;
Hodgson, A. ;
Kim, S. ;
Ding, C. ;
Saleeb, R. ;
Vesprini, D. ;
Liu, S. ;
Xu, B. ;
Yousef, G. .
VIRCHOWS ARCHIV, 2019, 475 :S171-S171
[23]   Gliosarcoma - A study of 13 tumors, including p53 and CD34 immunohistochemistry [J].
Sreenan, JJ ;
Prayson, RA .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1997, 121 (02) :129-133
[24]   Methodological variations for p53 detection by immunohistochemistry [J].
Ogden, GR .
ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1996, 32B (05) :365-365
[25]   Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins [J].
Chern, HD ;
Becich, MJ ;
Persad, RA ;
Romkes, M ;
Smith, P ;
Collins, C ;
Li, YH ;
Branch, RA .
JOURNAL OF UROLOGY, 1996, 156 (05) :1846-1849
[26]   p53 mutations in bladder tumors from arylamine-exposed workers [J].
Taylor, JA ;
Li, Y ;
He, M ;
Mason, T ;
Mettlin, C ;
Vogler, WJ ;
Maygarden, S ;
Liu, E .
CANCER RESEARCH, 1996, 56 (02) :294-298
[28]   Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors [J].
CordonCardo, C ;
Zhang, ZF ;
Dalbagni, G ;
Drobnjak, M ;
Charytonowicz, E ;
Hu, SX ;
Xu, HJ ;
Reuter, VE ;
Benedict, WF .
CANCER RESEARCH, 1997, 57 (07) :1217-1221
[29]   Preliminary results in detection of p53 mutations in bladder tumors with a functional assay [J].
Pfister, C ;
Flaman, JM ;
Dunet, F ;
Grise, P ;
Frebourg, T .
JOURNAL OF UROLOGY, 1998, 159 (05) :277-277
[30]   Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer [J].
Shiina, H ;
Igawa, M ;
Yagi, H ;
Urakami, S ;
Yoneda, T ;
Shirakawa, H ;
Ishibe, T .
ONCOLOGY, 1996, 53 (03) :233-240